Cargando…
The Impact of Absolute CD4 Count and Percentage Discordance on Pneumocystis Jirovecii Pneumonia Prophylaxis in HIV-Infected Patients
Current guidelines suggest that HIV-infected patients should receive chemoprophylaxis against Pneumocystis jirovecii pneumonia (PJP) if they have a cluster determinant 4 (CD4) count <200 cells/mm(3) or oropharyngeal candidiasis. Persons with CD4 percentage (CD4%) below 14% should also be consider...
Autores principales: | Anyimadu, Henry, Pingili, Chandra, Sivapalan, Vel, Hirsch-Moverman, Yael, Mannheimer, Sharon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748489/ https://www.ncbi.nlm.nih.gov/pubmed/29534652 http://dx.doi.org/10.1177/2325958218759199 |
Ejemplares similares
-
Acute Pneumocystis jirovecii Pneumonia Due to Absolute Lymphopenia
por: Hilker, Eric, et al.
Publicado: (2022) -
Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia
por: Heffelfinger, James D., et al.
Publicado: (2009) -
Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis
por: Dunbar, Albert, et al.
Publicado: (2020) -
Pneumocystis jirovecii Pneumonia Prophylaxis for Cancer Patients during Chemotherapy
por: Takeuchi, Kazuto, et al.
Publicado: (2021) -
PJP granuloma in an Immune competent host: Case report and literature review
por: Pingili, Chandra S., et al.
Publicado: (2017)